Delayed Nasdaq Stockholm 06:52:26 2024-04-30 am EDT 5-day change 1st Jan Change
27.85 SEK -0.71% Intraday chart for Genovis AB +0.72% -46.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Genovis to Get $1 Million Milestone Payment for Xork Development MT
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets CI
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ArcticZymes Technologies ASA and Genovis AB Announce Collaboration to Speed Up Penetration and Growth in the Chinese Market CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Genovis Signs Supply Agreement With US Biotech Company; Shares Rise 7% MT
Genovis AB Enters Licensing and Supply Agreement with New Bioprocess Customer CI
Genovis Starts Service Agreement with Swiss Biotech Company evitria MT
Genovis AB Enters Service Agreement with Evitria Ag for Fast LC_MSlysis of Recombinant Antibodies CI
Genovis AB (Publ.) Announces Board Changes CI
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021 CI
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Genovis AB Announces Exclusive License Agreement with Selecta Bioscience to Develop and Promote A Novel Igg Protease in Gene Therapy and Autoimmune Disease CI
Genovis' : New CFO To Assume Role January 2022 MT
Genovis AB (Publ.) Hires Magnus Långberg as the New CFO CI
Genovis AB (publ.) Announces Earnings Results for the Second Quarter Ended June 30, 2021 CI
Chart Genovis AB
More charts
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
28.05 SEK
Average target price
50.5 SEK
Spread / Average Target
+80.04%
Consensus
  1. Stock Market
  2. Equities
  3. GENO Stock
  4. News Genovis AB
  5. Genovis to Get $1 Million Milestone Payment for Xork Development